Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics (ITRM)
:ITRM
Total Valuation
Iterum Therapeutics has a market cap or net worth of $37.32M. The enterprise value is $982.79M.
Market Cap$37.32M
Enterprise Value$982.79M
Share Statistics
Iterum Therapeutics has 40,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,000,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Iterum Therapeutics’s return on equity (ROE) is 6.07 and return on invested capital (ROIC) is -45.54%.
Return on Equity (ROE)6.07
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-45.54%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee0.00
Profits Per Employee-2.75M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Iterum Therapeutics is -1.41. Iterum Therapeutics’s PEG ratio is >-0.01.
PE Ratio-1.41
PS Ratio0.00
PB Ratio0.37
Price to Fair Value-8.54
Price to FCF-0.55
Price to Operating Cash Flow-0.56
PEG Ratio>-0.01
Income Statement
In the last 12 months, Iterum Therapeutics had revenue of 0.00 and earned -24.77M in profits. Earnings per share was -1.26.
Revenue0.00
Gross Profit-254.00K
Operating Income-18.70M
Pretax Income-24.53M
Net Income-24.77M
EBITDA-18.70M
Earnings Per Share (EPS)-1.26
Cash Flow
In the last 12 months, operating cash flow was -16.75M and capital expenditures -2.00K, giving a free cash flow of -16.75M billion.
Operating Cash Flow-16.75M
Free Cash Flow-16.75M
Free Cash Flow per Share-0.42
Dividends & Yields
Iterum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.86
52-Week Price Change-33.75%
50-Day Moving Average1.00
200-Day Moving Average1.34
Relative Strength Index (RSI)58.74
Average Volume (3m)478.06K
Important Dates
Iterum Therapeutics upcoming earnings date is Aug 8, 2025, TBA (Confirmed).
Last Earnings DateMay 13, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Iterum Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of 101.67%
Current Ratio1.41
Quick Ratio1.41
Debt to Market Cap1.31
Net Debt to EBITDA-1.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Iterum Therapeutics has paid 240.00K in taxes.
Income Tax240.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Iterum Therapeutics EV to EBITDA ratio is -3.01, with an EV/FCF ratio of -2.10.
EV to Sales0.00
EV to EBITDA-3.01
EV to Free Cash Flow-2.10
EV to Operating Cash Flow-2.10
Balance Sheet
Iterum Therapeutics has $12.65M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$12.65M billion.
Cash & Marketable Securities$12.65M
Total Debt$0.00
Net Cash-$12.65M
Net Cash Per Share-$0.32
Tangible Book Value Per Share-$1.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Iterum Therapeutics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside560.38% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast55.67%